NRAS, KRAS, PTEN, and AKT mutations are associated with worse outcomes in patients newly diagnosed with T-ALL [39, 48, 49], are enriched in relapse specimens [38, 50], and have previously been shown to provide a proliferative advantage based on xenograft models [51]. This evidence concerns the gene NRAS and acute lymphoblastic leukemia.